Amgen has announced a $650 million expansion of its U.S. manufacturing facilities, a development that will create almost 750 new positions. The expansion will enhance drug production at the company’s biologics facility in Juncos while incorporating advanced technologies into its manufacturing processes.
“This expansion underscores Amgen’s commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “By growing our capacity to deliver innovative medicines with cutting edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America’s leadership in biotechnology.”
Puerto Rico Governor Jenniffer González Colón highlighted the mutually reinforcing relationship between the company and the local workforce. “Amgen’s multimillion-dollar expansion reflects a bond of mutual loyalty: Amgen’s sustained investment and Puerto Rico’s skilled, resilient workforce reinforcing each other over time,” she said. “This new expansion not only strengthens U.S. supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States.”
Supporting these remarks, Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce, emphasized the island’s enduring role in the sector. “Puerto Rico boasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure,” he said. “This investment by Amgen is a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper in Puerto Rico.”
Amgen’s U.S. manufacturing expansion is part of a broader pattern of domestic investment. Since the Tax Cuts and Jobs Act of 2017, the company has invested more than $40 billion in United States manufacturing and research and development. More recent pro-growth policies, supplemented by the One Big Beautiful Bill Act of 2025, have further enabled such domestic investments. Recent investments include a $600 million science and innovation center in California and manufacturing expansions of $900 million in Ohio and $1 billion in North Carolina.
